Forest Laboratories, Nycomed Group A/S deal

Nycomed granted Forest exclusive, U.S. rights to develop and commercialize Daxas roflumilast ( APTA-2217). In July, Nycomed submitted an NDA to FDA for the oral phosphodiesterase-4 (PDE-4) inhibitor...